Spinal cord injury - Articles - Page 4

Neurology/Psychiatric

Nurexone's Exopten nabs US orphan designation for acute spinal injury

Oct. 31, 2023

Nurexone Biologic Inc.'s regenerative therapy Exopten has been awarded orphan drug designation by the FDA to treat acute spinal cord injury.

Wandercraft launches commercial operations of its exoskeleton in the US

Oct. 19, 2023

By Shani Alexander

Wandercraft SAS has begun commercial operations of its exoskeleton, Atalante X, in the U.S., offering another solution to the millions of people living with mobility impairments. The company also formed a partnership with the Kessler Foundation whose research team will investigate the possible benefits of the Atalante X for neurologically impaired patients, including those recovering from stroke, spinal cord injuries and motor neuron disease.

Neurology/Psychiatric

Nurexone completes pre-IND meeting with FDA for Exopten for spinal cord injuries

Sep. 14, 2023

Nurexone Biologic Inc. has completed a pre-IND meeting with the FDA in connection with the manufacturing, preclinical and clinical development plan of Exopten. Exopten is being developed to be a minimally invasive Exotherapy product for spinal cord injuries given intranasally and yielding neuron regeneration and rewiring in traumatically damaged spinal cords.

Rewalk hopes for lift from $19M acquisition of anti-gravity systems for rehab

Aug. 9, 2023

By Annette Boyle

Rewalk Robotics Ltd. took strides to expand its portfolio—and achieve profitability—with an agreement to acquire Alterg Inc., a provider of anti-gravity systems for use in physical and neurological rehabilitation. Alterg uses NASA-derived differential air pressure (DAP) technology to reduce gravity’s effects on individuals with mobility challenges and pain. The $19 million deal is expected to close August 11, with additional cash earnouts tied to future revenue growth over the next two years.

Let there be walk: Onward Medical sees first use of movement-restoring lead

May 25, 2023

By Nuala Moran

The researchers who enabled patients with spinal cord injuries to walk independently after implanting programmable electrodes below their lesions have now taken things one step further, restoring direct communication from the brain to the spinal cord, enabling the brain rather than an external computer to direct leg movements.

Neurology/Psychiatric

Let there be walk: Onward Medical sees first use of movement-restoring lead

May 25, 2023

By Nuala Moran

The researchers who enabled patients with spinal cord injuries to walk independently after implanting programmable electrodes below their lesions have now taken things one step further, restoring direct communication from the brain to the spinal cord, enabling the brain rather than an external computer to direct leg movements.

Let there be walk: Onward Medical sees first use of movement-restoring lead

May 24, 2023

By Nuala Moran

The researchers who enabled patients with spinal cord injuries to walk independently after implanting programmable electrodes below their lesions have now taken things one step further, restoring direct communication from the brain to the spinal cord, enabling the brain rather than an external computer to direct leg movements.

Neurology/Psychiatric

Nurexone reports recovery of mice with spinal cord injuries after intranasal Exopten delivery

March 21, 2023

Nurexone Biologic Inc. has released further results from a preclinical study of Exopten demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.

Neurology/Psychiatric

Nurexone developing Exopten for spinal cord injury

Feb. 14, 2023

Nurexone Biologic Inc. is developing Exopten as a minimally invasive Exotherapy for spinal cord injuries (SCI). The company's platform produces and loads exosomes with pharmaceutical cargo, targeting SCI intranasally in the case of lead product Exopten.

Drug Design, Drug Delivery & Technologies

Intranasal antibody improves stroke symptoms

Jan. 19, 2023

By Nuala Moran

A noninvasive method for administering monoclonal antibodies reliably and reproducibly to central nervous system (CNS) targets remains a significant unmet need. Researchers in Switzerland have reported making headway in bypassing the blood-brain barrier through the intranasal delivery of full-length antibodies in rodent models. They show this delivery route leads to rapid transfer of significant amounts of a mouse antibody targeted against Nogo-A, a membrane protein that inhibits growth of neurites in the brain and spinal cord.